Mode
Text Size
Log in / Sign up
N/A N=40

Glycocalyx Damage in Critically Ill Patients

Critical Illness

Enrolled (actual)
40
Serious AEs
Results posted
Mar 2020
Primary outcome: Primary: Perfused Boundary Region (PBR) in One Week — 1.95; 1.97; 2.02 micrometer

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
PBR assessment (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University Hospital Hradec Kralove
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Perfused Boundary Region (PBR) in One Week
1.95; 1.97; 2.02

Summary

The hypothesis to be tested: GCX damage and its dynamics correlate to various patient related factors and to using organ-supporting measures. There is a correlation between length of organ support and GCX damage. The aim of the study: Evaluation of the relationship between GCX damage and duration of various organ supporting measures. Type of the study: Observational. Subjects: Adult patients admitted to ICU and requiring organ supporting therapy. Sample size: We plan enrollment of 75 patients on invasive ventilatory support in the duration of least 5 days, 50 patients on renal supporting therapy lasting at least 5 days and 20 patients with target temperature management for neuroprotection. Intervention: none Data to be recorded and analysed: Demographics, type of patients (trauma, post surgical, medical, after cardiac arrest), severity score - Apache II, SOFA, fluid balance, presence of delirium, clinical outcome, sublingual microcirculation by SDF imaging at time points: before or at the start of organ support, after 24 hours (day 1), day 3, 5, 7 and/or at discharge or before death, microcirculatory data, and Perfused Boundary Region.

Eligibility Criteria

Inclusion Criteria

  • adult patients admitted to ICU
  • artifitial ventilation
  • renal replacement therapy
  • targeted temperatura management

Exclusion Criteria

  • pregnant women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03146585). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search